RSV

RSV L-protein-IN-2 is a noncompetitive inhibitor of the Respiratory Syncytial Virus (RSV) polymerase, exhibiting an IC50 value of 4.5 μM. This compound demonstrates significant antiviral activity against long strains of RSV, with an EC50 of 1.3 μM. It is applicable in research focused on developing therapeutic strategies against RSV infections and understanding viral replication mechanisms.

BTA-9881 is a potent respiratory syncytial virus (RSV) inhibitor, demonstrating EC50 values of 48 nM, 59 nM, and 160 nM against RSV A2, RSV Long, and RSV B1, respectively. Its favorable pharmacokinetic properties make it a valuable reagent for studying RSV infection and evaluating potential antiviral therapies. BTA-9881 serves as an important tool in respiratory virus research, aiding in the development of effective treatments for RSV-related diseases.

JNJ-7184 is a non-nucleoside inhibitor targeting the RSV-Large (L) polymerase. This compound exhibits potent antiviral activity, demonstrating a pEC50 of 7.86 and a pCC50 of 4.29 in HeLa cells. JNJ-7184 effectively prevents respiratory syncytial virus (RSV) replication and transcription by disrupting the initiation and early elongation stages of the viral life cycle, making it a valuable tool for research into RSV pathogenesis and potential therapeutic strategies.

AZ-27 is a selective inhibitor of respiratory syncytial virus (RSV) by targeting its polymerase activity. This compound exhibits the ability to differentially suppress various RSV polymerase functions at the promoter level, effectively inhibiting the early stages of mRNA transcription and genome replication. AZ-27 is suitable for research applications focused on understanding RSV pathogenesis and developing antiviral strategies.

AZD4316 is an inhibitor of the respiratory syncytial virus (RSV) L protein, demonstrating significant antiviral activity against RSV A subtypes, including strain A2. This compound effectively hinders viral replication during the early stages of infection, particularly at the viral entry phase. However, its efficacy diminishes when administered 12-24 hours post-infection. AZD4316 is valuable for research focused on RSV infection mechanisms and potential therapeutic strategies.

RSV-IN-13 is a selective inhibitor of respiratory syncytial virus (RSV) fusion protein, exhibiting antiviral activity. It demonstrates an EC50 of 444.2 nM against the RSV A2 strain, with a CC90 of 23.7 μM in HepG2 cells. By effectively blocking the entry of the virus into host cells, RSV-IN-13 serves as a valuable tool for research on RSV infection and pathogenesis.

A 33903 is a selective inhibitor of respiratory syncytial virus (RSV) replication. It demonstrates significant antiviral activity against RSV, making it a valuable tool for researchers studying RSV infections and related therapeutic interventions. This reagent can facilitate investigations into viral pathogenesis and the development of antiviral strategies.

4,5-O-Dicaffeoyl quinic acid methyl ester is a potent antiviral agent specifically targeting respiratory syncytial virus (RSV). It exhibits strong inhibitory activity with an IC50 value of 0.63 μg/mL, indicating effective suppression of viral replication. The compound's safety profile is substantiated by a CC50 of 118.68 μg/mL, supporting its potential use in research applications focused on RSV-related therapeutic strategies.

PRRSV-IN-1 is a non-structural protein 4 (nsp4) protease inhibitor specifically targeting Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). This compound demonstrates potent antiviral activity, exhibiting an EC50 of 0.45 μM and effectively inhibiting nsp4 protease activity with an IC50 of 80.36 pM. PRRSV-IN-1 is a valuable tool for investigating antiviral strategies and understanding PRRSV pathogenesis in research applications.

Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV.

TMC353121 is a potent RSV fusion inhibitor in vitro, Antiviral agents and a novel candidate for RSV disease treatment.

PC786 is a potent non-nucleoside RSV L-protein polymerase inhibitor.

Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.

RSV604 racemate is a racemic mixture, shows less potency against strains of respiratory syncytial virus (RSV) than the S-isomer.

RSV604 R enantiomer is the R-enantiomer of RSV604. RSV604 is an inhibitor of respiratory syncytial virus (RSV) replication. R-enantiomer is less active against RSV.

Sisunatovir, also known as RV521, is a highly potent fusion inhibitor with efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses.

Enzaplatovir is an inhibitor of Respiratory Syncytial Virus (RSV). It can be used as a viral fusion protein inhibitor.

RSV604 is a novel inhibitor of respiratory syncytial virus replication(EC50=0.86 uM); a putative RSV nucleoprotein(N) inhibitor in phase 2 clinical trials.

ALS-8112 is a potent and selective respiratory syncytial virus (RSV) polymerase inhibitor. The 5'-triphosphate form of ALS-8112 inhibits RSV polymerase with an IC50 of 0.02 μM.

Ac-CoA Synthase Inhibitor1 is an anti-virus agent.

RSV-IN-1 is a human respiratory syncytical virus (hRSV) inhibitor, with an IC50 of 0.11 μM.

JNJ-678 (JNJ-53718678) is a novel fusion protein inhibitor in clinical trials for the treatment of respiratory syncytial virus (RSV).

Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor.

RD3-0028 is a potent and selective inhibitor of RSV replication with an EC50 of 4.5 μM.

Syncytial Virus Inhibitor-1 is a potent, orally bioavailable respiratory syncytial virus (RSV) fusion inhibitor with EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively.

JNJ-8003 is a highly potent, orally active non-nucleoside inhibitor of respiratory syncytial virus (RSV) polymerase, exhibiting an IC50 of 0.29 nM. It specifically targets the L protein of the polymerase complex, effectively blocking the transcription and replication of the viral genome by inhibiting RNA-dependent RNA polymerase (RdRp) activity, with an IC50 of 0.67 nM. In vitro studies demonstrate subnanomolar efficacy, and it has shown significant effectiveness in mouse and neonatal lamb models. JNJ-8003 is a valuable reagent for investigating RSV biology and developing antiviral therapies.

CL-A3-7 is a potent respiratory syncytial virus (RSV) inhibitor that targets the RSV F protein, functioning as a virus-cell fusion inhibitor. By disrupting the interaction between the virus and the host insulin-like growth factor 1 receptor (IGF1R), CL-A3-7 effectively prevents infections caused by both wild-type RSV and the K394R variant. This compound is valuable for use in anti-RSV drug development and studies focused on resistance mechanisms associated with RSV.

GS-646089 is a potent inhibitor of respiratory syncytial virus (RSV) RNA-dependent RNA polymerase (RdRp). This broad-spectrum antiviral nucleoside analog demonstrates robust activity against RSV, human metapneumovirus (hMPV), rhinovirus, and enteroviruses, with an IC50 in the range of 43 to 46 nM. GS-646089 is converted intracellularly into a triphosphate metabolite that competes with ATP for incorporation into growing RNA chains, effectively terminating viral replication. This compound serves as a valuable tool for research into acute respiratory viral infections and related viral pathogens.